Ventrica: Providing the Connection to Minimally Invasive Cardiac Surgery
In cardiac surgery, the slow shift to perform coronary bypass graft procedures off-pump has turned anastomotic device technology, a long dormant area of product development, into a hot subject at clinical meetings and attracted the attention of large and small device companies.
One start-up, Ventrica, was founded to focus on a new bypass procedure, but shifted its emphasis to an important component of that procedure: an automated coronary anastomotic connector. The company's magnetic technology has given it a head-start on this hardest part of the bypass connector puzzle.
Some industry experts and surgeons believe that an easy-to-use, reproducible, automated anastomotic device will boost adoption of off-pump bypass surgery, which has lagged far below initial expectations and will also be essential to the future of robotic surgery. Ventrica's challenge is to attract new groups of surgeons to this approach rather than simply preach to already-converted early adopters.
by Stephen Levin
Revolutions in clinical practice patterns and the device breakthroughs that either cause or accompany those changes are, like their political...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Worldwide medtech sales totaled $8.5bn in Q2, up 6.1%. Sales grew 8% in the US and 4.1% outside the US. Cardiovascular, surgery and vision were the primary growth drivers. Acquisitions and divestitures had net positive impact of 200 basis points, largely due to the acquisition of Shockwave Medical.
The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.
Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.
Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.
Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.
Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.
Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.